PubMed Health⌕ Search

PubMed · 12823014

Counterion effects on propylene polymerization using two-state ansa-metallocene complexes.

Abstract

Propylene polymerization using unsymmetrical, ansa-metallocene complexes Me(2)Y(Ind)CpMMe(2) (Y = Si, C, M = Zr, Y = C, M = Hf) and the co-initiators methyl aluminoxane (PMAO), B(C(6)F(5))(3), and [Ph(3)C][B(C(6)F(5))(4)] was studied at a variety of propylene concentrations. Modeling of the polymer microstructure reveals that the catalysts derived from Me(2)Si(Ind)CpZrMe(2) and each of these co-initiators function under conditions where chain inversion is much faster than propagation (Curtin-Hammett conditions). Surprisingly, the microstructure of the PP formed was essentially unaffected by the nature of the counterion, suggesting similar values for the fundamental parameters inherent to two-state catalysts. The tacticity of PP was sensitive to changes in [C(3)H(6)] in the case of catalysts derived from Me(2)C(Ind)CpHfMe(2) and PMAO, or [Ph(3)C][B(C(6)F(5))(4)], but the average tacticity of the polymer produced at a given [C(3)H(6)] decreased in the order [Ph(3)C][B(C(6)F(5))(4)] > PMAO. With B(C(6)F(5))(3), the polymer formed was more stereoregular, and its microstructure was invariant to changes in monomer concentration. The PP pentad distributions in this case could be modeled by assuming that all three catalyst/cocatalyst combinations function with different values for the relative rates of insertion to inversion (Delta) but otherwise feature essentially invariant, intrinsic stereoselectivity for monomer insertion (alpha, beta), while the relative reactivity/stability (g/K) of the isomeric ion-pairs present seems to be only modestly affected, if at all. Similar conclusions can also be made about the published propylene polymerization behavior of the C(s)-symmetric Me(2)C(Flu)CpZrMe(2) complex with different counterions. For every counterion investigated, the principle difference appears to be the operating regime (Delta) rather than intrinsic differences in insertion stereoselectivity (alpha). Surprisingly, the ordering of the various counterions with respect to Delta does not agree with commonly accepted ideas about their coordinating ability. In particular, catalysts when activated with B(C(6)F(5))(3) appear to function at low values of Delta as compared to those featuring B(C(6)F(5))(4) (less coordinating) and FAl[(o-C(6)F(5))C(6)F(4)](3) (more coordinating) or PMAO (more coordinating) counterions where the ordering in Delta is MeB(C(6)F(5))(3) < B(C(6)F(5))(4) < FAl[(o-C(6)F(5))C(6)F(4)](3) approximately PMAO. Possible reasons for this behavior are discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Muqtar Mohammed, Marcio Nele, Abdulaziz Al-Humydi, Shixuan Xin, Russell A Stapleton, Scott Collins. 2003-07-02. Counterion effects on propylene polymerization using two-state ansa-metallocene complexes.. https://doi.org/10.1021/ja0207706

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗